Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors
Chunrong Yang, Yuchen Yang, Yujie Li, et al.
Journal of the American Chemical Society (2022) Vol. 145, Iss. 1, pp. 385-391
Closed Access | Times Cited: 86

Showing 1-25 of 86 citing articles:

Annual review of PROTAC degraders as anticancer agents in 2022
Xiao Wang, Zhao-Long Qin, Na Li, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116166-116166
Closed Access | Times Cited: 53
Nanoscale Metal–Organic Framework with an X-ray Triggerable Prodrug for Synergistic Radiotherapy and Chemotherapy
Ziwan Xu, Wenyao Zhen, Caroline McCleary, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 34, pp. 18698-18704
Open Access | Times Cited: 46
Bioorthogonal chemistry for prodrug activation in vivo
Qunfeng Fu, Siyong Shen, Pengwei Sun, et al.
Chemical Society Reviews (2023) Vol. 52, Iss. 22, pp. 7737-7772
Closed Access | Times Cited: 45
Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity
Chuanjie Chen, Yiwen Yang, Zhe Wang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 8428-8440
Closed Access | Times Cited: 43
Self-Assembled Nano-PROTAC Enables Near-Infrared Photodynamic Proteolysis for Cancer Therapy
Weishan Wang, Chenghong Zhu, Bin Zhang, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 30, pp. 16642-16649
Closed Access | Times Cited: 41
New-generation advanced PROTACs as potential therapeutic agents in cancer therapy
Chao Wang, Yujing Zhang, Wujun Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 27
Radiotherapy activates picolinium prodrugs in tumours
Qunfeng Fu, 知子 谷, Siyong Shen, et al.
Nature Chemistry (2024) Vol. 16, Iss. 8, pp. 1348-1356
Closed Access | Times Cited: 22
Epigenetics-targeted drugs: current paradigms and future challenges
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 20
PROTAC technology: From drug development to probe technology for target deconvolution
Si Yan, Guangshuai Zhang, Wei Luo, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116725-116725
Closed Access | Times Cited: 19
Degraders upgraded: the rise of PROTACs in hematological malignancies
Joshua Casan, John F. Seymour
Blood (2024) Vol. 143, Iss. 13, pp. 1218-1230
Closed Access | Times Cited: 15
Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
Qiao‐Hong Chen, Erick Munoz, Dennis Ashong
Cancers (2024) Vol. 16, Iss. 3, pp. 663-663
Open Access | Times Cited: 15
PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies
Nuwayo Ishimwe Sincere, Krishnan Anand, Sumel Ashique, et al.
Molecules (2023) Vol. 28, Iss. 10, pp. 4014-4014
Open Access | Times Cited: 37
Stimuli-activatable PROTACs for precise protein degradation and cancer therapy
Jing Gao, Lei Yang, Shumin Lei, et al.
Science Bulletin (2023) Vol. 68, Iss. 10, pp. 1069-1085
Closed Access | Times Cited: 34
Stimuli‐Responsive PROTACs for Controlled Protein Degradation
Keli An, Xuqian Deng, Hongli Chi, et al.
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 39
Closed Access | Times Cited: 31
Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy
Jing Huang, Zhuo Yao, Bowen Li, et al.
Journal of Controlled Release (2023) Vol. 361, pp. 270-279
Closed Access | Times Cited: 25
Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies
Xiaopeng Peng, Zhihao Hu, Limei Zeng, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 2, pp. 533-578
Open Access | Times Cited: 25
PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 24
Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy
Zhifeng Zou, Lei Yang, Hui-Jun Nie, et al.
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 8, pp. 1740-1751
Closed Access | Times Cited: 13
Targeted protein degradation: advances in drug discovery and clinical practice
Guangcai Zhong, Xiaoyu Chang, Weilin Xie, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 13
Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety
Renshuai Zhang, Songbo Xie, Jie Ran, et al.
Journal of Cellular Physiology (2024) Vol. 239, Iss. 5
Closed Access | Times Cited: 10
A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy
Jing Gao, Xingyu Jiang, Shumin Lei, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 8
X‐ray controlled release strategy in cancer therapy
Yiling Ruan, Hongxiang Huang, Huihui Liu, et al.
BMEMat (2025)
Open Access | Times Cited: 1
Targeting intracellular cancer proteins with tumor‐microenvironment‐responsive bispecific nanobody‐PROTACs for enhanced therapeutic efficacy
Changping Deng, Jiacheng Ma, Yuping Liu, et al.
MedComm (2025) Vol. 6, Iss. 2
Open Access | Times Cited: 1
Nanotheranostics with Radionuclides for Cancer Diagnosis and Therapy
Minhui Cui, Mengmeng Zhu, Dongsheng Tang, et al.
Advanced Functional Materials (2025)
Closed Access | Times Cited: 1
Novel approaches to targeted protein degradation technologies in drug discovery
Yu Xue, Andrew A. Bolinger, Jia Zhou
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 4, pp. 467-483
Closed Access | Times Cited: 21
Page 1 - Next Page

Scroll to top